USFDA observations at Patalganga and Kurkumbh facilities
Patalganga received six 483 observations and Kurkumbh one; official classification awaited, potentially delaying product approvals.
high · management_commentaryCipla Ltd — Q4 FY24
Cipla reported Q4 FY24 revenue of INR 6,163 crore, up 10% YoY, with EBITDA margin expanding 95 bps to 21.4%.
bullish
high
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Trade generics channel restructuring disruption
Transition to direct stockist model may cause temporary hiccups in Q1 FY25, impacting trade generics growth.
medium · analyst_questionTiming uncertainty for Goa plant reinspection and Abraxane launch
Goa plant reinspection expected around July-August 2024; Abraxane launch depends on inspection outcome and subsequent 90-day process.
medium · analyst_questionPotential pricing pressure in Lanreotide market
As a two-player market, pricing may vary depending on competitor actions, though management aims to grow total value.
low · analyst_question